Trial | NCT01284478  Report issue

Title

Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery
Phase 2 Study of Ozurdex for Combined Pseudophakic Cystoid Macula Edema and Diabetic Macula Edema After Cataract Surgery

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    urea ...

  • Study Participants

    6
The purpose of the study is to determine where a sustained steroid delivery system (Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients after Cataract Surgery
Study Started
Jan 31
2011
Primary Completion
Oct 31
2012
Study Completion
Oct 31
2012
Last Update
Oct 04
2012
Estimate

Drug Dexamethasone Implant

Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally

Dexamethasone Implant Other

Patients will be treated with the Ozurdex (Dexamethasone Implant)

Criteria 

Inclusion Criteria:

DIABETIC PATIENTS WHO DEVELOP CYSTOID MACULA EDEMA AFTER CATARACT SURGERY (WITHIN 4-10 WEEKS AFTER SURGERY
VISUAL ACUITY WORSE THAN 20/32

Exclusion Criteria:

VISUAL ACUITY WORSE THAN 20/200
MODERATE OR SEVERE GLAUCOMA (AS DEFINED AS USING >2 TOPICAL GLAUCOMA MEDIATIONS.
USE OF SYSTEMIC, PERIOCULAR OR INTRAOCULAR CORTICOSTEROIDS WITHIN 30 DAYS OF ENROLLMENT
No Results Posted